Phosphatidylinositol 3-kinase mutations associated with ovarian, colon and breast tumours

与卵巢、结肠和乳腺肿瘤相关的磷脂酰肌醇 3 激酶突变

• 批准号: nhmrc : 288712
• 负责人: Prof Ian Campbell
• 金额: $ 10.27万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phosphatidylinositol-3-kinase-breast-tumours/98377
• 关键词: Phosphatidylinositol; kinase; mutations; associated; ovarian

Colorectal and breast cancers are the two most common registrable cancers in Australia and are second only to lung cancer in the total number of cancer deaths each year (4,678 and 2,612 deaths in 1997 for colorectal and breast, respectively). Ovarian cancer kills a further 740 women each year (Source: Cancer in Australia 1997, AIHW and AACR 2000). Thus, on average, one Australian dies of colorectal, breast or ovarian cancer every hour! Clearly, these are major diseases with a significant impact on our society. Unfortunately, though, we still do not understand the basic molecular and-or biochemical abnormalities that initiate and-or drive the development of these cancers. Recent functional and genetic studies in a number of different tumour types (including colon and ovarian) have suggested that members of the phosphatidylinositol 3-kinase (PI3K) enzyme family may be oncogenes (cancer-causing genes). However, strong evidence confirming a causal role for PI3K in human cancer is yet to be reported. Our research proposal outlines a study to address this issue. We have preliminary data demonstrating mutations in at least one member of this enzyme family in a number of tumours. We now propose to undertake a comprehensive analysis of the spectrum, and frequency, of PI3K mutations that occur in colon, breast and ovarian tumours. These studies will allow us to make a definitive assessment of the role of PI3K in the development human cancer. In addition to furthering our understanding of the processes involved in the initiation and progression of human tumours, this project also has the potential to identify new markers for the early detection of cancer and novel targets for new anti-cancer therapies.

结直肠癌和乳腺癌是澳大利亚最常见的两种可登记癌症，在每年癌症死亡总数中仅次于肺癌（1997 年结直肠癌和乳腺癌分别有 4,678 人和 2,612 人死亡）。卵巢癌每年夺去 740 名女性的生命（来源：澳大利亚癌症 1997 年，AIHW 和 AACR 2000）。因此，平均每小时就有一名澳大利亚人死于结直肠癌、乳腺癌或卵巢癌！显然，这些都是对我们社会产生重大影响的重大疾病。但不幸的是，我们仍然不了解引发和/或驱动这些癌症发展的基本分子和/或生化异常。最近对多种不同肿瘤类型（包括结肠癌和卵巢癌）的功能和遗传学研究表明，磷脂酰肌醇 3-激酶 (PI3K) 酶家族的成员可能是癌基因（致癌基因）。然而，尚未有强有力的证据证实 PI3K 在人类癌症中的因果作用。我们的研究提案概述了解决这一问题的研究。我们有初步数据证明该酶家族的至少一个成员在多种肿瘤中存在突变。我们现在建议对结肠癌、乳腺癌和卵巢肿瘤中发生的 PI3K 突变的谱和频率进行全面分析。这些研究将使我们能够对 PI3K 在人类癌症发展中的作用做出明确的评估。除了进一步加深我们对人类肿瘤发生和进展过程的理解外，该项目还有可能确定用于早期检测癌症的新标记物和新抗癌疗法的新靶点。